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ABSTRACT
Sorafenib is an orally active tyrosine kinase inhibitor used in the
treatment of renal and hepatocellular carcinoma. This study was
designed to establish whether transport proteins are involved in the
hepatic uptake of sorafenib and to determine the extent of biliary
excretion of sorafenib and its metabolites in human hepatocytes.
Initial uptake was assessed in freshly isolated, suspended hu-
man hepatocytes in the presence of inhibitors and modulators.
[14C]Sorafenib (1 mM) uptake at 4°C was reduced by about 61–63%
of the uptake at 37°C, suggesting a high degree of passive dif-
fusion. Hepatocyte uptake of [14C]sorafenib was not Na+ depen-
dent or influenced by the organic anion transporter 2 inhibitor
ketoprofen. However, initial [14C]sorafenib hepatocyte uptake
was reduced by 46 and 30% compared with control values in the
presence of the organic anion transporting polypeptide inhibitor
rifamycin SV and the organic cation transporter (OCT) inhibitor
decynium 22, respectively. [14C]Sorafenib (0.5–5 mM) uptake was
significantly higher in hOCT1-transfected Chinese hamster ovary
cells compared with mock cells, and inhibited by the general
OCT inhibitor, 1-methyl-4-phenylpryidinium. OCT1-mediated uptake
was saturable with a Michaelis-Menten constant of 3.80 6 2.53
mM and a Vmax of 116 6 42 pmol/mg/min. The biliary excretion
index and in vitro biliary clearance of sorafenib (1 mM) in
sandwich-cultured human hepatocytes were low (∼11% and 11
ml/min/kg, respectively). Results suggest that sorafenib uptake
in human hepatocytes occurs via passive diffusion, by OCT1,
and by organic anion transporting polypeptide(s). Sorafenib un-
dergoes modest biliary excretion, predominantly as a glucuronide
conjugate(s).
Introduction
Sorafenib (Fig. 1), an orally active multikinase inhibitor, blocks
tumor cell proliferation by targeting Raf/mitogen activated protein
kinase/extracellular signal-regulated kinase and exerts an antiangio-
genic effect by targeting vascular endothelial growth factor receptor-
1/-2/-3 and platelet-derived growth factor receptor-b tyrosine kinases
(Wilhelm et al., 2004). Sorafenib is approved for the treatment of renal
and hepatocellular carcinomas and has demonstrated activity toward
other malignancies (Ratain et al., 2006; Miller et al., 2009).
After oral administration of [14C]sorafenib to healthy volunteers,
approximately 77% of a 100-mg oral dose was excreted in feces (51%
as parent), and 19% of the dose was excreted in urine as glucuronidated
metabolites; approximately 17% of circulating radioactivity in plasma
was in the form of sorafenib N-oxide (Lathia et al., 2006). Sorafenib
oxidative metabolism is mediated by CYP3A4 yielding the N-oxide
sorafenib metabolite. Sorafenib also undergoes glucuronidation by the
uridine diphosphate-glucuronosyl-transferase (UGT1A9) pathway (Fig.
1) (Lathia et al., 2006). Peak plasma concentrations of sorafenib occur
within 2 to 3 hours after a single oral dose (Strumberg et al., 2005);
secondary peaks in the plasma concentration-time profile have been
attributed to enterohepatic recirculation of sorafenib after cleavage of
the glucuronide conjugate or reduction of the N-oxide in the gastroin-
testinal tract (Lathia et al., 2006). High interpatient variability in the
Cmax and the area under the concentration-time profile (AUC) in human
plasma of sorafenib and the primary metabolite, sorafenib N-oxide have
been reported after multiple oral doses of sorafenib (Strumberg et al.,
2007; Miller et al., 2009). Variability in pharmacokinetics can be caused
by interindividual differences in the metabolizing enzymes or the trans-
port proteins, which also are subject to polymorphisms. Understanding
the mechanisms of hepatic uptake and the extent of biliary excretion
of sorafenib is particularly important in patients with unresectable
hepatocellular carcinoma, where the target site of sorafenib is the liver.
Transport proteins can play an important role in the clearance of
drugs from hepatic sinusoidal blood and the excretion of the parent
drug and/or metabolite(s) across the apical membrane into the bile
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canaliculus. The basolateral proteins that mediate the uptake of en-
dogenous and exogenous compounds into hepatocytes include mem-
bers of the solute carrier superfamily: Na+-taurocholate cotransporting
polypeptide (NTCP), organic anion transporters (OATs), organic
cation transporters (OCTs), and organic anion transporting polypep-
tides (OATPs). NTCP, which is expressed exclusively in the liver, is
Na+ dependent and predominately accounts for the uptake of bile acids
(Ho et al., 2004). Recently, a few drugs, such as rosuvastatin, have
been reported to be NTCP substrates (Ho et al., 2006). The OATPs
exhibit broad and overlapping substrate specificity and display an
affinity for organic anions as well as some bulky cations and neutral
steroids (Mikkaichi et al., 2004). In contrast to NTCP, the OATPs
operate in an Na+-independent manner and function as bidirectional
carriers (Li et al., 2000; Briz et al., 2006; Mahagita et al., 2007). Three
human isoforms— OATP1B1, 1B3, and 2B1—play a substantial role
in the hepatic uptake of many endogenous and exogenous compounds,
including bilirubin (Konig et al., 2000; Cui et al., 2001), fexofenadine
(Cvetkovic et al., 1999), and many statins (Shitara and Sugiyama,
2006). OCTs are electrogenic uniporters that mediate primarily the
transport of small cations, although the transport of anions and un-
charged compounds has been reported (Koepsell et al., 2003). The
OATs constitute a family of proteins that mediate transport of neg-
atively charged endogenous and exogenous compounds in exchange
for dicarboxylate ions. OATs are expressed predominantly in the
kidney, although OAT2 has higher expression on the sinusoidal mem-
brane of hepatocytes compared with the basolateral membrane of
proximal kidney tubules (Sun et al., 2001). Transporters located in the
apical membrane involved in the removal of drug and metabolite(s)
into the bile canaliculus include P-glycoprotein (P-gp), multidrug
resistance–associated protein (MRP2), breast cancer resistance protein
(BCRP), and the bile salt export pump. Sorafenib is a weak substrate
for P-gp, but the overall effect of this transporter on plasma concen-
trations is low based on in vivo results using mdr1a/1b(-/-) knockout
mice (Gnoth et al., 2010).
The objective of the present study was to determine whether transport
proteins are involved in the hepatic uptake of sorafenib and to determine
the extent of biliary excretion of sorafenib and its metabolites in human
hepatocytes. Initial uptake was assessed in freshly isolated human
hepatocytes and in OCT1-transfected Chinese hamster ovary (CHO)
cells. Sandwich-cultured human hepatocytes were used to determine the
hepatobiliary disposition of sorafenib and metabolites.
Materials and Methods
Materials. Dulbecco’s modified Eagle’s medium (DMEM), F-12 Nutrient
Mixture, minimum essential medium nonessential amino acids solution (100),
L-glutamine, penicillin G-streptomycin solution (100), gentamicin, and
penicillin G-streptomycin-amphotericin B solution (100) were purchased from
Invitrogen (Carlsbad, CA). Rifamycin SV, ketoprofen, dexamethasone, TEA,
1,1-dimethyl-biguanide hydrochloride (metformin), fetal bovine serum, Triton X-
100, HEPES, D-glucose, dexamethasone, trypsin-EDTA solution (1), and
Hanks’ balanced salt solution (HBSS) modified with (H-1387) or without (H-
4891) calcium chloride were obtained from Sigma-Aldrich (St. Louis, MO).
Sorafenib tosylate (purity 99.7%), [14C]sorafenib (3.09 MBq/mg radiochemical
purity 99.2%), the internal standard [2H3,
15N] sorafenib tosylate, and decynium
22 were provided by Bayer HealthCare AG (Wuppertal, Germany). [14C]TEA
(55 mCi/mmol) was purchased from American Radiolabeled Chemicals (St.
Louis, MO). [14C]Biguanide (metformin, 110 mCi/mmol) was purchased from
Moraveck Biochemicals (Brea, CA). ITS+ (insulin/transferrin/selenium) culture
supplement was purchased from BD Biosciences Discovery Labware (Bedford,
MA). Bicinchoninic acid (BCA) protein assay reagents and bovine serum
albumin for the protein assay standard were purchased from Pierce Chemical Co.
(Rockford, IL). Ultima Gold XR scintillation cocktail was purchased from
PerkinElmer Life Sciences (Boston, MA). All other chemicals and reagents were
of analytical grade and available from commercial sources.
Suspended Hepatocyte Isolation and Uptake Studies. CellzDirect, Life
Technologies (Research Triangle Park, NC), kindly provided freshly isolated
human hepatocytes in suspension. Hepatocyte donors were a 60-year-old
Caucasian woman and a 63-year-old Caucasian man with no recent history of
smoking or alcohol use. Hepatocyte viability, as determined by trypan blue
exclusion, was 89 and 90%. Cells were suspended in cold modified Hank’s
Fig. 1. Chemical structure of sorafenib and metabolic
pathways.
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buffer with 10 mM Tris/5 mM glucose (pH 7.4) or Na+-free choline buffer
(10 mM Tris, 5 mM glucose, 5.4 mM KCl, 1.8mM CaCl2, 0.9 mM MgSO4,
10 mM HEPES, and 137 mM choline; pH 7.4) and stored on ice before uptake
studies were performed (Leslie et al., 2007). Isolated hepatocytes were
suspended in the same buffer (1  106 cells/ml), placed on ice, and used
immediately in experiments. Hepatocyte suspensions (1 ml; n = 2 livers, in
triplicate) were preincubated in 16  100-mm glass test tubes at 37°C for 3
minutes; 0.1% dimethysulfoxide or chemical inhibitor was added 1 minute
before [14C]sorafenib (0.9 mM; 3.86 nCi; 0.9% methanol). The following
concentrations of inhibitors were selected based on reported affinities for the
given active transport processes: 20 mM rifamycin SV (OATP1B1, OATP1B3,
and OATP2B1 inhibitor), 5 mM decynium 22 (OCT inhibitor), and 10 mM
ketoprofen (OAT2 inhibitor). Aliquots (100 ml) of the suspension were
removed at timed intervals (up to 2.5 minutes), placed in 0.4-ml polyethylene
tubes, and centrifuged immediately through a top layer of silicone oil:mineral
oil (82:18, v/v; 100 ml) into a bottom layer of 3 M KOH (50 ml). [14C]Sorafenib
in the cell pellet and supernatant were analyzed by liquid scintillation counting.
Adherent fluid volume was estimated with [14C]inulin as described previously
(Baur et al., 1975). Protein concentrations for individual hepatocyte sus-
pensions were determined with the BCA protein assay reagent kit (Pierce) as
instructed by the manufacturer. Bovine serum albumin, as supplied by the
manufacturer, was used as a standard (0.2–1 mg/ml).
Transport Studies in hOCT1-Expressing CHO Cells. Transport studies
were carried out 5 days postseeding, as previously described (Ming et al.,
2009). Briefly, stably transfected CHO cells were grown as monolayers in 24-
well plates, and the medium was changed every other day. Cells were
preincubated for 30 minutes at 37°C in transport buffer (HBSS with calcium
chloride, 25 mM D-glucose, and 10 mM HEPES, pH 7.4). Experiments were
initiated by replacement of the transport buffer with 0.4 ml of varying amounts
of radiolabeled dose solutions in transport buffer. Initially, time-dependent
experiments were conducted for up to 30 minutes to determine the linear
uptake range (unpublished data). For concentration-dependent experiments,
uptake was determined in the mock cells or CHO-OCT1 cells over a 10-
minute period. Inhibition of OCT1-mediated uptake was performed in mock
or CHO-OCT1 cells by concomitantly incubating 500 mM MPP+ (1-methyl-
4-phenylpryidinium) with the substrate [14C]sorafenib. After incubation, dose
solutions were aspirated and cells were washed four times with 4°C transport
buffer. Cells were lysed with 500 ml of 0.1 N NaOH/0.1% SDS for 4 hours on
an orbital shaker, and samples were analyzed by liquid scintillation counting.
Data were normalized to protein concentration in each well, determined in
duplicate aliquots using BCA protein assay reagent kit, as detailed above.
For estimation of Michaelis-Menten (Km) parameters, OCT1-mediated
uptake was determined as the difference in cell associated radioactivity in the
hOCT1-transfected and mock cells at each substrate concentration. The Km and
Vmax values were obtained by fitting the Michaelis-Menten equation V = Vmax •
[S]/(Km + [S]) to the data using WinNonlin v.5.2.1 (Pharsight, Mountain View,
CA), where V represents the velocity of substrate transport, [S] refers to the
concentration of substrate, and Km is defined as the concentration of substrate at
the half-maximal transport rate (Vmax).
Sandwich-Cultured Human Hepatocyte Studies. B-CLEAR-Human kits
were purchased from Qualyst, Inc. (Research Triangle Park, NC). Human
hepatocytes isolated from two different subjects (Table 1) were seeded at
approximately 1.75  106 cells/well on six-well BioCoat plates in DMEM
without phenol red supplemented with 2 mM L-glutamine, 1% (v/v) minimum
essential medium nonessential amino acids, 100 units penicillin G sodium, 100
mg streptomycin sulfate, 1 mM dexamethasone, 5% (v/v) fetal bovine serum,
and 10 mM insulin (day 0 of culture) and allowed to attach for 2–6 hours in
a humidified incubator (95% O2, 5% CO2) at 37°C. After cell attachment,
culture plates were swirled gently, and the culture medium was replaced with
the same medium. Cells were overlaid 16–24 hours (day 1 of culture) after
seeding with ice-cold Matrigel basement membrane matrix (0.25 mg/ml) in
2 ml/well cold serum-free DMEM containing 2 mM L-glutamine, 1% (v/v)
minimum Eagle’s medium nonessential amino acids, 100 units penicillin G
sodium, 100 mg streptomycin sulfate, 1 mM dexamethasone, and 1% (v/v)
ITS+ (insulin/transferrin/selenium). The culture medium was changed every
24 hours until experiments were performed on day 7 of culture.
Accumulation Studies. The method to determine substrate accumulation in
sandwich-cultured hepatocytes has been described previously (Leslie et al.,
2007; Wolf et al., 2008). Cells were incubated for 20 minutes at 37°C with 1.5
ml of sorafenib solution (1 and 10 mM). Medium samples were collected
immediately, and hepatocytes were rinsed vigorously three times with 2 ml of
ice-cold standard buffer after the incubation. Substrate uptake was corrected for
nonspecific binding by subtracting uptake on blank six-well Biocoat plates
overlaid with Matrigel. Data were normalized to protein concentration in each
well, determined in duplicate with the BCA protein assay reagent kit. Because
of incompatability of the protein assay with organic solvent, the average protein
concentration for standard HBSS or Ca2+-free HBSS incubations in the same
liver preparation was used to normalize sorafenib content. Sorafenib-treated
hepatocytes were stored immediately at 280°C until analysis. The cells were
lysed with 1 ml of mobile phase containing internal standard, scraped off the
plates and centrifuged at 10,000  g for 5 minutes before analysis by liquid
chromatography coupled with tandem mass spectrometry.
Sample Analysis. Sorafenib and sorafenib N-oxide concentrations were
determined by a liquid chromatography coupled with tandem mass spectrom-
etry assay using a LTQ Orbitrap XL (Thermo Scientific, Bremen, Germany)
coupled to an Agilent 1200 system (Agilent Technology, Waldbronn,
Germany). Sorafenib and its metabolites were eluted from a Synergi Hydro
RP 2.5-mm column (20  2 mm internal diameter; Phenomenex, Torrance, CA)
using a mobile phase gradient at a flow rate of 0.3 ml/min (A: 0.05% formic
acid in water; B: 0.05% formic acid in acetonitrile); 0 minutes 30% B, 5
minutes 60% B, 5.3 minutes 30% B. The column effluent was monitored using
a LTQ Orbitrap XL (Thermo Scientific) by quantification of the exact mass of
sorafenib, internal standard, sorafenib N-oxide, and sorafenib glucuronide.
The calibration ranged from 1 ng/ml to 1000 ng/ml. The lower limit of
quantification for sorafenib was 2 ng/ml and 1 ng/ml for sorafenib N-oxide.
Data Analysis. For accumulation studies in sandwich-cultured hepatocytes,
the biliary excretion index (BEI, %) and in vitro biliary clearance (in vitro
Clbiliary) were calculated using B-CLEAR technology [Qualyst, Inc.; (Liu et al.,
1999)]:
BEI ¼ AccumulationCellsþBile 2AccumulationCells
AccumulationCellsþBile
 100
where substrate accumulation in the cells+bile compartments was determined
in hepatocytes preincubated in standard buffer; cellular accumulation of
substrate was determined in hepatocytes preincubated in Ca2+-free HBSS.
In   Vitro    Clbiliary ¼ AccumulationCellsþBile 2AccumulationCellsAUC02T
where AUC0-T was calculated using the log trapezoidal method; the theoretical
dosing concentration was used for t = 0 and the final medium concentration for
t = incubation time. In vitro Clbiliary values were scaled per kilogram of body
weight using 0.948 (liver 1) and 1.35 (liver 2) mg of protein per well, assuming
the following: 1 mg protein/1.75  106 cells, 107  106 hepatocytes per gram
of human liver tissue, and 25.7 g of liver tissue per kg of body weight, as
previously described (Davies and Morris, 1993).
Statistically significant differences in sorafenib uptake in transfected
CHO cells were determined by a two-way analysis of variance followed by
the Bonferroni post hoc test. The criterion for significance in all cases was
P , 0.05.
TABLE 1
Demographics, BEI, and Clbiliary of [
3H]taurocholate in sandwich-cultured
human hepatocytes
Donors had no history of tobacco or alcohol use or comedications; body mass index (BMI);
sandwich-cultured hepatocytes were incubated with 1 mM [3H]taurocholate (10 minutes). Results
are presented as representative data from triplicate determinations in two livers.
Liver Donor
Identification
Age Gender Race BMI
Taurocholate
BEI % In Vitro Clbiliary
yr kg/m2 ml/min/kg
Liver 1 44 Female Caucasian 24 64.8 59.9
Liver 2 48 Female Caucasian 21.7 62.6 32.4
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Results
Uptake of Sorafenib in Suspended Human Hepatocytes. Initial
uptake of [14C]sorafenib into suspended human hepatocytes was linear
up to about 1.5 minutes (Fig. 2, A and B). Uptake at 4°C was reduced
by about 61–63% of the uptake at 37°C (Fig. 2, A–D). [14C]Sorafenib
uptake at all the time points sampled (Fig. 2, C and D) did not exhibit
sodium dependence (average [14C]sorafenib uptake was about 4, 13,
and 14% greater than control values when sodium was replaced with
choline in the uptake buffer at 0.5, 1.5, and 2.5 minutes, respec-
tively), and it was not influenced significantly by ketoprofen (uptake
was decreased by only 4% compared with control uptake). Initial
[14C]sorafenib uptake was reduced by 26, 46, and 42% of control
values in the presence of the OATP inhibitor rifamycin SV at 0.5, 1.5,
and 2.5 minutes, respectively, and reduced by 25, 30, and 39% of
control values in the presence of the OCT inhibitor decynium 22 at
0.5, 1.5, and 2.5 minutes, respectively (Fig. 2, C and D; 2.5-minute
data not shown).
Transport of Sorafenib in OCT1-Transfected CHO Cells. As
expected, uptake of 10 mM [14C]metformin (unpublished data) and 5
mM [14C]TEA in OCT1-transfected CHO cells was increased around
7-fold compared with mock cells, confirming OCT1 function in these
cells (Fig. 3A). The uptake of 5 mM [14C]TEA was completely abated
in the presence of 500 mM MPP+ (Fig. 3A).
[14C]Sorafenib uptake was significantly higher in OCT1-transfected
CHO cells compared with mock cells over the concentration range
examined (0.5–5 mM). OCT1-mediated uptake was saturable with
a Km of 3.80 6 2.53 mM and Vmax of 116 6 42 pmol/mg/min. The
OCT inhibitor, MPP+, decreased [14C]sorafenib uptake in OCT1-
transfected and mock CHO cells, suggesting that other MPP+ sensitive
transport processes are involved in sorafenib uptake (Fig. 3B). MPP+
reduced [14C]sorafenib uptake in mock cells by ;49–63%, suggesting
that passive diffusion plays a role in sorafenib uptake, consistent with
data generated in suspended human hepatocytes at 4°C.
Hepatobiliary Dispostion of Sorafenib in Human Sandwich-
Cultured Hepatocytes. The hepatobiliary disposition of [3H]taur-
ocholate and sorafenib was measured in human sandwich-cultured
hepatocytes. After a 10-minute incubation with 1 mM [3H]taurocho-
late, the BEI and in vitro Clbiliary for both livers (Table 1) were
consistent with previous data generated in this model system. The
cellular accumulation of sorafenib appeared to be dose dependent
(Table 2). Sorafenib cellular accumulation was approximately 2 orders
of magnitude greater than the primary metabolite sorafenib N-oxide
after a 20-minute incubation at the 1 mM sorafenib dose, and greater
than 1 order of magnitude at the 10 mM sorafenib dose (Table 2).
The BEI of sorafenib in sandwich-cultured human hepatocytes was
low (;11%). The sorafenib in vitro Clbiliary was moderately low at 1
and 10 mM sorafenib (;11 ml/min/kg), ranging from approximately
one-third to one-fifth of the taurocholate in vitro Clbiliary values in each
of the liver donors (Tables 1 and 2). After a 20-minute incubation with
either 1 or 10 mM sorafenib, sorafenib N-oxide concentrations were
below the detection limit (,1 ng/ml) in medium, except for the 10 mM
dose in hepatocytes prepared from the second liver; however, longer
incubation times of 60 and 120 minutes resulted in slightly higher
medium concentrations of sorafenib N-oxide (Fig. 4). The BEI of
sorafenib glucuronide at the 1 mM dose was negligible for both liver
donors at 20 minutes; sorafenib glucuronide was detected in medium at
all the time points and increased with the longer incubation time. The
biliary excretion of sorafenib glucuronide increased with incubation time
(BEI = 0, 42, and 40% at 20, 60, and 120 minutes, respectively) (Fig. 4).
Discussion
Hepatic transport proteins are recognized increasingly as important
determinants of the pharmacokinetics of many drugs, as well as key
sites of drug-drug interactions (Soars et al., 2009). Genetic poly-
morphisms of uptake transport proteins also have been implicated in
Fig. 2. Uptake of [14C]sorafenib (0.9 mM) in
suspended human hepatocytes from two
separate donors (A and B) over 2.5 minutes.
Hepatocytes were incubated at 37°C (d) or
4°C (s) in standard buffer (mean 6 S.D.;
n = 2 livers in triplicate). Initial uptake of
[14C]sorafenib (0.9 mM) at 0.5 minutes (C)
and 1.5 minutes (D) in suspended human
hepatocytes incubated at 37°C in standard
buffer, unless otherwise specified, and in the
presence of transport protein modulators,
including choline buffer, inhibitors (rifamy-
cin SV, decynium 22, and ketoprofen) and
lower incubation temperature (n = 2 livers;
mean percentage 6 range).
1182 Swift et al.
interindividual differences in the pharmacokinetics and pharmacody-
namics of clinically relevant drugs such as the statins (Ieiri et al.,
2009). In the present study, the transport proteins involved in the
hepatic uptake of sorafenib were investigated, and the hepatobiliary
disposition of sorafenib and metabolites was assessed.
Sorafenib is a very lipophilic compound (log D7 = 5.16; predicted
properties SciFinder Scholar, version 2007, CAS, Columbus, OH).
The initial uptake of sorafenib in human hepatocytes was examined at
37°C versus 4°C to assess the contribution of passive diffusion to
overall uptake. The initial uptake of [14C]sorafenib at 4°C was reduced
by 61 and 63% at 0.5 and 1.5 minutes, respectively, compared with
37°C, which suggests a high degree of passive diffusion (Fig. 2, A–D).
The contribution of passive diffusion versus carrier mediated uptake
remains unclear as a result of the effect of temperature on both
processes. There was also a high degree of passive diffusion in CHO
cells (Fig. 3B). Furthermore, greater than 54% of the sorafenib dose
partitioned into human sandwich-cultured hepatocytes after a 20-
minute incubation with 1 mM sorafenib based on the mass of drug
remaining in the media at the end of the incubation period in relation
to the initial dose (Table 2). These findings are in agreement with
the reported high Papp in the absorptive direction of 16.4 6 12.3 and
33.5 6 16.1  1026 cm/s for 0.1 and 1 mM sorafenib, respectively,
determined in Caco-2 cells (Gnoth et al., 2010).
The active uptake of [14C]sorafenib (0.9 mM) was investigated with
transport protein modulators. Rifamycin SV (20 mM) was selected as
an inhibitor of all the relevant human isoforms of OATP expressed in
the liver: OATP1A2, OATP1B1, OATP1B3, and OATP2B1 (Vavricka
et al., 2002). Decynium 22 (5 mM) was used as an OCT inhibitor
(Zhang et al., 1997; Hayer-Zillgen et al., 2002), and OAT2 function
was inhibited with ketoprofen (10 mM) (Morita et al., 2001; Ohtsuki
et al., 2002). To assess Na+-dependent transport by NTCP, choline-
based buffer was substituted for Na+-based buffer in suspended
hepatocytes. The sensitivity of the transport proteins and specificity to
the inhibitors rifamycin SV and decynium 22 were confirmed in the
presence and absence of the model probe substrates [3H]estradiol-17-
b-D-glucuronide (OATP substrate) and [14C]TEA (OCT substrate), as
published previously (Swift et al., 2010). Sorafenib uptake at all time
points sampled was sensitive to rifamycin SV and decynium 22,
Fig. 3. Uptake of the positive control (A) [14C]TEA (5 mM) was assessed in CHO-OCT1 cells in the absence (white bar) and presence (hatched bar) of 500 mM MPP+ and
mock cells (black bar). Uptake of (B) [14C]sorafenib (0.5–5 mM) in CHO-hOCT1 cells. CHO-hOCT1 cells were incubated in the absence (m) and presence (D) of 500 mM
MPP+, and mock cells in the absence (d) and presence (s) of 500 mM MPP+ at 10 minutes. Inset: OCT1-mediated [14C]sorafenib transport determined as the difference in
uptake in CHO-hOCT1 and mock cells at each substrate concentration. The curve represents the best fit of the Michaelis-Menten equation to the OCT1-mediated uptake data.
Data represent mean 6 S.D. (n = 3); *P , 0.001 OCT1 versus mock; †P , 0.001 OCT1 versus OCT1+MPP+; ††P , 0.001 mock versus mock+MPP+; when error bars are
not visible, they are smaller than the symbol.
TABLE 2
Accumulation, BEI, and Clbiliary of sorafenib or sorafenib N-oxide in sandwich-cultured human hepatocytes
Sandwich-cultured hepatocytes were incubated with 1 and 10 mM sorafenib for 20 minutes. Results are presented as mean 6 S.D. from triplicate experiments from two livers.




Cells + Bile Cells
pmol/ml pmol/ml pmol/ml ml/min/kg
Liver 1 Sorafenib 1 mM 39.1 6 2.3 1210 6 230 1570 6 70 0 NA
Liver 2 460 6 16 917 6 41 819 6 23 11 11.1
Liver 1 Sorafenib 10 mM 475 6 59 7200 6 130 6760 6 550 6 11.1
Liver 2 1600 6 75 6430 6 130 5760 6 240 10 11.5
Liver 1 N-oxide (sorafenib 1 mM) BLQ (,1.00) 9.89 6 2.62 12.3 6 0.5 0 NA
Liver 2 BLQ (,1.00) 6.91 6 0.22 6.14 6 0.22 11 NA
Liver 1 N-oxide (sorafenib 10 mM) BLQ (,1.00) 80.8 6 5.1 63.2 6 12.9 22 NA
Liver 2 11.8 6 4.6 361 6 13 346 6 27 4 NA
BLQ, below the limit of quantitation; NA, not applicable.
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suggesting that the OATPs and OCTs are involved in the hepatic
uptake this tyrosine kinase inhibitor (Fig. 2, C and D). The contribu-
tion of OATP1B1 and OATP1B3 to the hepatic uptake of sorafenib
has been confirmed in vitro (Zimmerman et al., 2013). The in-
volvement of OCT1 in sorafenib uptake was investigated further
using a hOCT1-expressing CHO cell line. This finding contradicts
work by Hu et al., who reported no appreciable uptake of sorafenib by
Xenopus laevis oocytes expressing OCT1, OATP1A2, OATP1B1, or
OATP1B3 (Hu et al., 2009). This apparent discrepancy could be
explained by experimental differences. For example, in the present
studies, sorafenib uptake into CHO cells was saturable after 10
minutes; Hu et al., incubated sorafenib with X. laevis oocytes for 1
hour, possibly masking the active uptake component. Furthermore,
different in vitro model systems may yield conflicting data. For
example, Agarwal et al. (2011) conclusively demonstrated the
transport of sorafenib by Bcrp both in vitro and in vivo, in contrast
to the data generated in LLC-PK1 cells transfected with BCRP (Hu
et al., 2009; Agarwal et al., 2011). Imatinib, another tyrosine kinase
inhibitor, is an OCT1 substrate in the human T-lymphoblastoid cell
line CCRF-CEM (Thomas et al., 2004). Some substrate overlap exists
between OCTs and OATPs, which have an affinity for numerous type
II (bulky) cations such as N-methylquinine (van Montfoort et al.,
1999). Furthermore, the class of tyrosine kinase inhibitors has been
shown to inhibit metformin uptake in OCT-transfected cell lines
(Minematsu and Giacomini, 2011).
Decynium 22 inhibition of sorafenib uptake in suspended human
hepatocytes was likely due to OCT1 based on further studies
demonstrating that OCT1-mediated uptake of sorafenib was signifi-
cantly higher in OCT1-transfected CHO cells compared with mock
cells over the concentration range examined (0.5–5 mM) (Fig. 3B).
These results are the first to demonstrate that sorafenib is a substrate of
OCT1 with a Km of 3.8 mM. Interestingly, sorafenib uptake in
nontransfected mock cells was inhibited partially by MPP+, suggesting
that other MPP+-sensitive endogenous transport proteins in the CHO
cell line are involved in sorafenib uptake. The unknown transport
protein(s) that is/are sensitive to MPP+ in mock CHO cells may be
present in human hepatocytes. We cannot rule out the possibility that
rifamycin SV inhibited the uptake of sorafenib by this unknown
transport protein(s) in the suspended hepatocyte experiments.
To investigate the hepatobiliary disposition of sorafenib, studies
were performed in human sandwich-cultured hepatocytes. The dosing
concentrations (1 and 10 mM) used in these studies were in the range
of the reported total maximum plasma concentration (5 to 21 mM)
after multiple oral doses of sorafenib (100–600 mg twice daily)
(Strumberg et al., 2005), but higher than the expected unbound plasma
concentration of sorafenib based on reported binding to plasma
proteins (99.5% bound; package insert). Sorafenib, a P-gp and Bcrp
substrate (Hu et al., 2009; Gnoth et al., 2010; Agarwal et al., 2011),
exhibited a relatively low BEI (up to 11%; Table 2) and in vitro
Clbiliary (up to 11.5 ml/min/kg), which is not surprising because of the
extent of CYP3A4- and UGT1A9-mediated metabolism observed in
vivo (Lathia et al., 2006). The model bile acid [3H]taurocholate, which
is generally considered to have a high hepatic clearance, was included
as a system control in the two liver donors, but it also serves as a good
reference point for compounds with high BEI (64.8 and 62.6%) and
high in vitro Clbiliary (59.9 and 32.4 ml/min/kg) (Table 1).
Biotransformation of sorafenib to the N-oxide is mediated primarily
by CYP3A4 (Lathia et al., 2006; Ghassabian et al., 2012). The low
formation of sorafenib N-oxide in day 7 human sandwich-cultured
hepatocytes may be due to lower cytochrome P450 enzyme activity
after isolation and culture (Hoen et al., 2000; Boess et al., 2003).
Dexamethasone is a prototypical cytochrome P450 inducer that is
added to cell culture medium. In the present studies, dexamethasone
concentrations in the culture medium were only 1 mM, which is much
lower than the 10 mM or higher concentrations used in some human
and rat sandwich-cultured hepatocyte studies to induce CYP3A4 and
Cyp3A1/2 protein expression and increase activity of CYP3A4 and
Cyp3A1/2, as measured by testosterone 6b-hydroxylation (LeCluyse
et al., 1996). Sorafenib N-oxide is the primary circulating metabolite
in human plasma (Lathia et al., 2006); concentrations of sorafenib N-
oxide in medium, a surrogate for blood, increased with the longer
incubation times. Although no glucuronide was detected in the bile of
sandwich-cultured hepatocytes after a 20-minute incubation, sorafenib
glucuronide was excreted into bile after incubation of hepatocytes with
sorafenib for 60 and 120 minutes, as demonstrated with the higher BEI
(40–42%) (Fig. 4). The increased formation and biliary excretion of
sorafenib glucuronide after longer incubation times may partially
explain the significant amount of parent drug recovered in feces after
oral dosing [;77% of a 100 mg oral dose was excreted in feces, of
which 51% was the parent drug (according to the package insert)].
Based on our results, we hypothesize that sorafenib glucuronide
undergoes biliary excretion; a portion of the glucuronide conjugate is
cleaved in the gastrointestinal tract; subsequently, generated sorafenib
is reabsorbed. This hypothesis is supported by the clinical observation
of secondary peaks in the sorafenib plasma concentration-time profile
(Lathia et al., 2006). Sorafenib glucuronide also was detected in the
medium of sandwich-cultured hepatocytes (Fig. 4), in agreement with
the findings that glucuronidated metabolites of sorafenib are recovered
in human urine after oral administration.
Sorafenib metabolites, specifically the glucuronide conjugates,
require transport proteins for biliary excretion and basolateral efflux.
As mentioned, sorafenib is a P-gp and BCRP substrate and may also
be an MRP2 substrate (Shibayama et al., 2011), suggesting that these
transport proteins may play a role in the biliary excretion of sorafenib
and its metabolites. MRP2 is responsible for the biliary excretion of
many glucuronide conjugates of drugs, as well as bilirubin conjugates
(Kamisako et al., 1999), and may transport sorafenib glucuronide into
bile. Clinically relevant drug interactions associated with impaired
biliary clearance have been reported for digoxin with coadministration
of the P-gp inhibitors quinidine, verapamil, and ritonavir (Fenner
et al., 2009). Furthermore, it is well recognized that patients with liver
Fig. 4. Ratio of amount of sorafenib and formed metabolites in (cells + bile)/(cells +
bile + medium) in day 7 sandwich-cultured human hepatocytes from liver 2
incubated with 1 mM sorafenib for 20 (solid bars), 60 (open bars), and 120 (hatched
bars) minutes. The BEI was calculated after triplicate determination of substrate
accumulation in cells and cells + bile. A standard was unavailable for sorafenib
glucuronide, so the peak area under the curve divided by the internal standard area
under the curve was used.
1184 Swift et al.
disease develop adaptive changes in transport protein expression;
these adaptations protect the hepatocyte from the intracellular accu-
mulation of toxic compounds such as bile acids. In fact, many patients
with hepatocellular carcinoma develop cirrhosis, which results in the
downregulation of basolateral uptake transport proteins often coupled
with the upregulation of canalicular and basolateral efflux proteins
(Zollner et al., 2003, 2007). This highlights the importance of under-
standing the mechanisms of sorafenib hepatobiliary disposition.
In conclusion, sorafenib uptake in suspended human hepatocytes,
CHO cells and sandwich-cultured human hepatocytes was extensive.
Uptake into human hepatocytes was temperature dependent and de-
creased approximately 61–63% at 4°C, suggesting a high degree of
passive diffusion. The active portion of hepatic uptake was sensitive to
rifamycin SV and decynium 22, suggesting the involvement of OATPs
and OCT, respectively. OCT1-mediated uptake of sorafenib was con-
firmed in OCT1 overexpressing CHO cells. Sorafenib undergoes modest
biliary excretion as the parent compound; biliary excretion of the major
metabolites, N-oxide and glucuronide conjugate(s), is increased with
incubation time in sandwich-cultured hepatocytes.
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